Very poor CEO job by Dan. Looks like pricing is indicative of RT002 viewed as another ‘botox’ wannabe that will make no difference to AGN market share.
Now he is stupid to run additional trials and will surely run out of money necessitating another rise down the road. Any Partnership in Revance’s terms is increasingly unlikely.